Quintrio
Home

AGRICULTURAL CHEMICALS

SenesTech, Inc. Common Stock

SNES

SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company has developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Its current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.

Last trade $0.7583
Day change -$0.0142 (-1.84%)
Day range $0.756 – $0.859
Volume 11,929
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.25M
Price / earnings
—
Price / book
1.14×
Price / sales
1.89×
EV / sales
0.53×
EV / EBITDA
-0.19×

Profitability

Earnings per share
-$1.12
Return on assets
-94.01%
Return on equity
-166.49%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.03×
Current ratio
4.51×
Quick ratio
3.73×
Cash ratio
3.2×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SNES, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.1M$770K$493K$421K$690K$625K$485K$501K
Cost of revenue$301K$203K$155K$188K$257K$216K$172K$196K
Gross profit$796K$567K$338K$233K$433K$409K$313K$305K
Selling, general and administrative$2.37M$2.05M$2.04M$1.66M$1.38M$1.6M$1.56M$1.14M
Research and development$418K$377K$422K$453K$400K$427K$418K$424K
Total operating expenses$2.79M$2.43M$2.46M$2.11M$1.78M$2.02M$1.98M$1.56M
Operating income-$1.99M-$1.86M-$2.12M-$1.88M-$1.35M-$1.61M-$1.66M-$1.26M
Interest expense-$5K-$5K-$4K-$5K-$6K-$6K-$5K-$7K
Income before taxes-$1.96M-$1.83M-$2.06M-$1.8M-$1.3M-$1.62M-$1.67M-$1.26M
Income taxes$0$0$0$0$0$0$0$0
Net income-$1.96M-$1.83M-$2.06M-$1.8M-$1.3M-$1.62M-$1.67M-$1.26M
Net income attributable to common shareholders-$1.96M-$1.83M-$2.06M-$1.8M-$1.3M-$1.62M-$1.67M-$1.26M
EBITDA-$1.96M-$1.83M-$2.09M-$1.85M-$1.32M-$1.58M-$1.62M-$1.22M
Basic earnings per share-$0.36-$0.35-$0.39-$0.34-$0.28-$0.87-$1.28-$1.21
Diluted earnings per share-$0.36-$0.35-$0.39-$0.34-$0.28-$0.87-$1.28-$1.21

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

SenesTech Expands E-Commerce Reach Through Walmart Fulfillment Services

SenesTech, Inc. (NASDAQ: SNES) announced that its Evolve rodent birth control products are now available through Walmart Fulfillment Services (WFS), expanding distribution on Walmart.com. The transition from direct company fulfillment to WFS enables faster delivery, reduces fulfillment costs, and increases product visibility. The company reports that this change is already contributing to increased sales on Walmart.com, supporting its ecommerce growth strategy.

Benzinga

SenesTech Announces Amendment to Equity Incentive Plan Proposal

SenesTech's Board of Directors approved an amendment to reduce the number of new shares proposed for its 2018 Equity Incentive Plan from 1.7 million to 1.2 million shares ahead of the June 9, 2026 Annual Meeting of Stockholders. The company cited anticipated equity compensation needs, current market conditions, and stockholder considerations in making this balanced approach to capital management.

Benzinga

SenesTech Announces CEO Transition Plan

SenesTech Inc (NASDAQ: SNES) announced that President and CEO Joel Fruendt plans to retire. The Board will conduct a formal search for a successor, with Fruendt remaining in his position until the search concludes or June 30, 2026, whichever comes first. Dr. Jamie Bechtel has been appointed Interim Executive Chair to support the transition, while interim COO Michael Edell and CFO Tom Chesterman will continue leading day-to-day operations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 25, 20241-for-10reverse split
Nov 17, 20231-for-12reverse split
Nov 16, 20221-for-20reverse split
Sep 1, 20222-for-1stock dividend
Feb 5, 20201-for-20reverse split